Original communication| Volume 109, ISSUE 6, P706-714, June 1991

A new anticancer drug delivery system for the management of carcinomatous peritonitis

      This paper is only available as a PDF. To read, Please Download here.


      To develop a new drug delivery system for the treatment of carcinomatous peritonitis, we constructed 5-fluorouracil poly L-microcapsules (5Fu-mc) by the organic phase separation technique and examined their drug-releasing capacities and anticancer effects. The microcapsules consisted of in vitro dissolvable polymolecular poly L-lactic acid and 5-fluorouracil (5Fu). The 5Fu-mc was about 200 μm in diameter and had a 5Fu content of about 40% (weight/weight). 5Fu-release time from the microcapsules was about 50 hours in vitro and about 48 hours in vivo. After the release of the 5Fu, the poly L-lactic acid was metabolized very slowly in the peritoneal cavity. The 5Fu-mc caused fewer side effects than the equivalent dose of a 5Fu solution. In addition, macroscopic and microscopic examinations of various abdominal organs revealed no toxic effects from the microcapsules. After administration of 5Fu-mc into the abdominal cavity of rats with AH-130 carcinomatous peritonitis, the 5Fu concentration remained at a high level for an extended period in the ascites but fell rapidly to low levels in the plasma. In conclusion, the present studies indicated that the 5Fu-mc were much more effective in prolonging the life of tumor-bearing hosts while producing less systemic side effects than a 5Fu solution.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tubian M
        • Richard JM
        • Malaise E
        Kinetics of tumor growth and of cell proliferation in U.R.D.T. cancers—therapeutic implications.
        Laryngoscope. 1975; 85: 1039-1052
        • Widder KJ
        • Senyei AE
        • Ranney DF
        Magnetically responsive microspheres and other cancers for the biophysical targeting of antitumor agents.
        Adv Pharmacol Chemother. 1979; 6: 212-271
        • Hashiba M
        • Egawa M
        • Muranishi S
        • Sezaki H
        Role of intramuscular administration of water—in oil emulsions as a method for increasing the delivery of anticancer agents to regional lymphatics.
        J Pharmacokinet Biopharm. 1977; 5: 225-239
        • Gregoiadis G
        Targeting of drugs.
        Nature. 1977; 265: 407-411
      1. Higuchi T Stella V Pro-drug as novel drug delivery systems. American Chemical Society Publications, Washington1975: 1-115
        • Sutherland LG
        • Weisberger AS
        Intracavitary 5-fluorouracil in malignant effusions.
        Arch Intern Med. 1965; 116: 431-433
        • Ruszynyak I
        • Fold M
        • Szabo G
        Absorption of waterland crystalloid molecules from serous cavities: lymphatics & lymph circulation—physiology & pathology.
        in: 2nd ed. Pregman press, London1967: 495-501
        • Spratt JS
        • Adcock RA
        • Muskovin M
        Clinical delivery system for intraperitoneal hyperthermic chemotherapy.
        Cancer Res. 1980; 40: 256-260
        • Kato T
        • Nemoto R
        Microencapsulation of mitomycin C for intraarterial infusion chemotherapy.
        in: 5th ed. Proc Jpn Acad. 54. 1978: 413-417
        • Lee TK
        • Sokoloski TD
        • Royer GP
        Serum albumin beads an injectable biodegenerable system for the sustained release of drugs.
        Science. 1981; 212: 233-235
        • Takahashi T
        • Mizuno M
        • Fujita Y
        • Ueda S
        • Nishioka B
        • Majima S
        Increased concentration of anticancer agents in regional lymph nodes by fat emulsion with special reference to chemotherapy of metastasis.
        Jpn J Canc Res. 1973; 64: 345-350
        • Hashiba M
        • Kato A
        • Kojima T
        Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.
        Jpn J Canc Res. 1981; 72: 226-234
        • Garnett MC
        • Embleton MJ
        • Jacobs E
        • Baldwin RW
        Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro.
        Int J Cancer. 1983; 31: 661-670
        • Hagiwara A
        • Takahashi T
        • Lee R
        • Ueda T
        • Takada M
        • Ito T
        Selective delivery of high levels of mitomycin C to peritoneal carcinomatosis using a new dosage form.
        Anticancer Res. 1986; 6: 1161-1164
        • Kulkarni RK
        • Pani KC
        • Neuman C
        • Leonard F
        Polylactic acid for surgical implants.
        Arch Surg. 1966; 93: 839-843
        • Cutright DE
        • Hunsuck EE
        The repair of fractures of the orbital floor using biodegradable polylactic acid.
        Oral Surg. 1972; 33: 28-43
        • Getter L
        • Cutright DE
        • Bhaskar SN
        • Augusburg JK
        A biodegradable intraosseous appliance in the treatment of mandibular fractures.
        J Oral Surg. 1972; 30: 344-348
        • Alexander H
        • Parsons JR
        • Strauchler ID
        • Corcoran SF
        Canine patellar tendon replacement with a polylactic acid polymer-filamentous carbon degrading scaffold to form new tissue.
        Orthop Rev. 1981; 10: 41-45
        • Miller RA
        • Brady JM
        • Cutright DE
        Degradation rats of oral resorbable implants (polylactates and polyglycolates)—rats modification with changes in Math Eq copolymer ratios.
        J Biomed Mater Res. 1977; 11: 711-719
        • Duschinsky R
        • Pleven E
        • Heiderberger C
        The synthesis of 5-Fluoro-pyrimidines.
        J An Chem Soc. 1967; 79: 4559-5460
        • Ansfield FJ
        • Schroeder JM
        • Curreri AR
        Five years clinical experience with 5-fluorouracil.
        J A M A. 1962; 181: 295-299
        • Heiderberger C
        • Ansfield F
        Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy.
        Cancer Res. 1963; 23: 1226-1243
        • Fu JC
        • Kale A
        • Moyer DL
        Diffusion of pyrimethamine from silicone rubber and flexible epoxy drug capsules.
        J Biomed Mater Res. 1973; 7: 193-200